Exclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not

Adaptin Bio is launching with plans to bring a bispecific T cell engager for glioblastoma, a deadly form of brain cancer, into the clinic. …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex­clu­sive: Duke spin­out launch­es in hopes of pre­vail­ing with brain can­cer bis­pe­cif­ic where Am­gen, Roche did not